IQVIA CEO Ari Bousbib Reports Strong Q2 Results, Exceeding Expectations and Driving Growth

Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted D...

July 23, 2024 | Tuesday | Company results
Shanghai Junshi Biosciences' sNDA for Toripalimab and Bevacizumab Combo for Advanced Liver Cancer Accepted by NMPA

  Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...

July 19, 2024 | Friday | News
Boehringer Ingelheim Chairman von Baumbach Highlights Strong H1 2024 Performance and Pipeline Milestones

Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncology Further data read-outs expected in 2024 in oncology, mental health, ...

July 18, 2024 | Thursday | News
Paul Limburg Highlights Commitment to Reducing Screening Disparities Through the FOCUS Program's Support of 28 Organizations Nationwide

  Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced  that it awarded a total of $1.5 million to 28 organiza...

July 18, 2024 | Thursday | News
Novartis CEO Vas Narasimhan Announces Impressive Q2 2024 Results: 11% Net Sales Surge and Upgraded FY2024 Guidance

net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entr...

July 18, 2024 | Thursday | Company results
Breaking Barriers in CAR T Cell Therapy: Martin Westberg on How the Sefia Platform is Transforming Manufacturing

In this insightful interview with Martin Westberg, Vice President and General Manager of Cell Therapy at Cytiva, BioPharma BoardRoom delve into the tr...

June 06, 2024 | Thursday | Interview
Merck CEO Belén Garijo Forecasts Organic Growth Recovery in 2024 Amid Solid First Quarter Performance

Financial results of Q1 2024 Healthcare with strong performance Electronics increases sales and earnings organically, driven by higher demand for semic...

May 15, 2024 | Wednesday | Company results
Charles River's CEO, James C. Foster, Optimistic About Growth Amidst First-Quarter Performance

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 bil...

May 13, 2024 | Monday | Company results
Bio-Rad's CEO, Norman Schwartz, Finds Hope in Adversity: "Our Vision Remains Strong Despite Market Challenges"

  First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023...

May 08, 2024 | Wednesday | Company results
Driving Global Access to Medicines: A Conversation with Cem Zorlular, CEO of Er-Kim

  In an interview with BioPharma BoardRoom, Cem Zorlular, CEO of Er-Kim, shares his personal journey and the driving force behind Er-Kim's mission to...

May 06, 2024 | Monday | Interview
Twist Bioscience Sees Strong Growth, Revenue Reaches $75.3M in Q2FY24," Says CEO Emily M. Leproust

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today ...

May 03, 2024 | Friday | News
Emma Walmsley, CEO of GSK, Highlights Strong Start to 2024 with Impressive Performance and Pipeline Progress

Broad-based performance drives sales, profits and earnings growth: Total Q1 2024 sales £7.4 billion +10% and +13% ex COVID Vaccines sales +16...

May 02, 2024 | Thursday | Company results
QIAGEN's Quantum Leap: CEO Thierry Bernard Heralds First Quarter Triumph with Stellar Growth in Key Areas!

Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 Net ...

April 30, 2024 | Tuesday | Company results
Gilead's CEO Daniel O'Day Projects Robust Growth in 2024 Amidst Promising Acquisition and Pipeline Advancements

Gilead Sciences Announces First Quarter 2024 Financial Results Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy...

April 26, 2024 | Friday | Company results

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in